Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03713632 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

SUNRISE
Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety and tolerability of secukinumab.

NCT ID: NCT03713619 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

SUNSHINE
Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety and tolerability of secukinumab.

NCT ID: NCT03661866 Not yet recruiting - Psoriasis Clinical Trials

A 5-year Study of Patients Treated for Atopic Dermatitis and Other IMISC

TARGET-DERM
Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

NCT ID: NCT03221621 Not yet recruiting - Clinical trials for Hidradenitis Suppurativa

Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

HS-COST
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a maximum of three surgeries after two years of treatment in adult patients with moderate to severe HS.